Rib-X Pharmaceuticals, Inc. Reports Additional Positive Delafloxacin Data at ICAAC, Including Performance Against New Objective Endpoints From FDA, From Its Completed Phase 2b Study in Patients With Acute Bacterial Skin and Skin Structure Infections

Published: Sep 12, 2012

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc., today presented new efficacy and safety results from the Company’s Phase 2b clinical trial of delafloxacin for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by methicillin- and quinolone- resistant Staphylococcus aureus (MRSA, QRSA). Results from the Phase 2b trial and other clinical and preclinical studies were presented in seven poster presentations and a symposium session at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 9-12, 2012 in San Francisco, CA.

Back to news